ライフサイエンスコーパス: progressive disease

1 (14 with nonprogressive disease and 15 with progressive disease).

2 e response, indeterminate, partial response, progressive disease).

3 t on day 40; the death was deemed related to progressive disease.

4 e determined according to RECIST 1.1 to have progressive disease.

5 response, minor response, stable disease, or progressive disease.

6 % (3 of 17) stable disease and 30% (5 of 17) progressive disease.

7 this category than for those with stable or progressive disease.

8 Seven patients died, three of whom due to progressive disease.

9 % (4 of 15) stable disease and 20% (2 of 15) progressive disease.

10 mg), 31 showed stable disease, and eight had progressive disease.

11 ransformed cases or accurately predict early progressive disease.

12 ed treatment before study end, mainly due to progressive disease.

13 change in SUV to define partial response and progressive disease.

14 th advanced soft tissue or bone sarcoma with progressive disease.

15 remains a need for effective treatments for progressive disease.

16 se, including 6 of 8 entering the study with progressive disease.

17 response and n=11 stable local disease, one progressive disease.

18 erved kidney function, but not in those with progressive disease.

19 table disease, and three (19%, 4.1-45.7) had progressive disease.

20 ecrease in erythropoiesis in BM in mice with progressive disease.

21 n, 19 mo; interquartile range, 14-26 mo) had progressive disease.

22 ith multiple comorbidities in the setting of progressive disease.

23 Chronic kidney disease (CKD) is a highly progressive disease.

24 rompt treatment can be initiated if there is progressive disease.

25 erichia coli sepsis), each in the setting of progressive disease.

26 ts with stable disease than in patients with progressive disease.

27 d stable disease, and two (9%, 1.1-28.0) had progressive disease.

28 ts with EAC to determine L1 activity in this progressive disease.

29 ers of a single node can be used to identify progressive disease.

30 stable disease; the remaining four (9%) had progressive disease.

31 able disease and the remaining two (10%) had progressive disease.

32 eatment of colonized patients with severe or progressive disease.

33 onse, five had stable disease, and seven had progressive disease.

34 achieved partial remission, and 1 of 51 had progressive disease.

35 e domain of ALK, resulting in resistance and progressive disease.

36 esponse, 28 had stable disease, and four had progressive disease.

37 ions that result in ibrutinib resistance and progressive disease.

38 isk of graft loss from recurrent amyloid and progressive disease.

39 xcept in cases of visceral crisis or rapidly progressive disease.

40 in RRMS, making it a potential biomarker of progressive disease.

41 n = 2) after stopping venetoclax because of progressive disease.

42 jority of patients who eventually succumb to progressive disease.

43 criteria, ranging from complete response to progressive disease.

44 Nearly half of the patients presented with progressive disease.

45 tures than patients with partial response or progressive disease.

46 being a potential therapy for patients with progressive disease.

47 eath unrelated to study treatment was due to progressive disease.

48 children with a negative family history and progressive disease.

49 favorable in 3 patients, whereas 4 exhibited progressive disease.

50 drawal of consent, unacceptable toxicity, or progressive disease.

51 ossible exception of a subgroup with rapidly progressive disease.

52 and therapeutic candidate for patients with progressive disease.

53 5% CI, 161-274 Gy; n = 13) and patients with progressive disease (116 Gy; 95% CI, 81-165 Gy; n = 9) (

54 (P = 0.01) and between complete response and progressive disease (117 Gy; 95% CI, 87-159 Gy; n = 21)

55 the primary reasons for discontinuation were progressive disease (21%) and AEs (11%).

56 176 pwMS with relapsing disease than 92 with progressive disease (2124.8 ng/L, SD 3348.9 vs 1121.4 ng

57 inued in 54 (44%) patients, primarily due to progressive disease (39 [31%]) and adverse events (seven

58 98 [39%] of 252; five related to treatment), progressive disease (43 [17%]), sepsis (36 [14%]; two re

59 te or partial response than in patients with progressive disease (95% CI, 20%-180%).

60 ase after treatment (hazard ratio, 0.017 vs. progressive disease; 95% confidence interval, 0.001-0.35

61 Twenty-three (32%) patients with progressive disease according to PERCIST5 had controlled

62 lear distinction between tumor shrinkage and progressive disease according to RECIST.

63 rmal organ function and centrally documented progressive disease according to Response Evaluation Cri

64 rtial response) and nonresponders (stable or progressive disease) according to PERCIST1 and PERCIST5

65 tients) were a priori divided into stable vs progressive disease, according to gross motor and cognit

66 PED appears to be the primary indicator for progressive disease activity, whereas secondary cystoid

67 Friedreich's ataxia (FRDA) is a progressive disease affecting multiple organs that is ca

68 ents with metastatic solid malignancies with progressive disease after >/= one line of palliative che

69 Two patients developed progressive disease after a complete response for 38 mon

70 e in heavily treated patients with mCRPC and progressive disease after docetaxel and abiraterone and/

71 stage study, we enrolled adult women who had progressive disease after first-line chemotherapy for ad

72 sies; an ECOG performance status of 0-1; and progressive disease after previous treatment with at lea

73 One additional patient developed progressive disease after the 6-mo follow-up period but

74 Patients with progressive disease after two or more HER2-directed regi

75 y of patients with newly diagnosed cancer or progressive disease aimed at identifying patients at ris

76 d stable disease, and six (29%) patients had progressive disease; all responses were across a variety

77 In cases of progressive disease, an additional evaluation was perfor

78 Two patients died as a result of GVHD, 1 of progressive disease and 1 of complications related to a

79 ith multiple sclerosis (seven with secondary progressive disease and 14 with a relapsing remitting di

80 ent emphysema at CT were more likely to have progressive disease and increased mortality at 5 years c

81 unoregulatory qualities of PD-1 and IL-10 in progressive disease and link exhausted virus-specific CD

82 ial response than among those with stable or progressive disease and those who had received secondary

83 e opportunity to treat patients with rapidly progressive disease and where autologous CAR-T-cell ther

84 sease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as ris

85 onse, 17 cases as stable disease, 5 cases as progressive disease, and 14 cases as HPD.

86 ; 180 (36%) had adverse events, 70 (14%) had progressive disease, and 51 (10%) requested to stop trea

87 was markedly suppressed in IPF subjects with progressive disease, and both TGF-beta1 and SHH signalin

88 omplete or partial response, stable disease, progressive disease, and HPD (P = 0.001).

89 ve and disease-free, eight (16%) had died of progressive disease, and one patient (2%) each had died

90 ctive pulmonary disease (COPD) is a chronic, progressive disease, and reversal of COPD diagnosis is t

91 However, many HLA-B*57 patients develop progressive disease, and some studies have suggested tha

92 ML is currently indicated only for recurrent progressive disease, and the acute and long-term toxicit

93 combine to define the transition to NASH and progressive disease are complex, and consequently, no ph

94 ess the most common components of radiologic progressive disease as defined by RECIST 1.1 in patients

95 We used Alzheimer's disease (AD), a complex progressive disease, as a model because the well-establi

96 ith no need for immediate therapy to rapidly progressive disease associated with therapeutic resistan

97 One patient had progressive disease at 0.4 months.

98 nfidence interval, 65-84) were alive without progressive disease at 6 months (primary end point).

99 nivolumab or docetaxel was longer than after progressive disease at 6 months, with hazard ratios for

100 s on bevacizumab and 11% on temsirolimus had progressive disease at 6 weeks.

101 Two deaths occurred due to progressive disease at 7 mo.

102 ients in this trial, 184 had symptomatic and progressive disease at baseline.

103 Progressive disease at bone scintigraphy was evident in

104 as associated with worse PFS ( P < .001) and progressive disease at first restaging ( P < .001).

105 us, with both patients having no evidence of progressive disease at last follow-up.

106 week 12 (delayed) that was not confirmed as progressive disease at next assessment.

107 of progressive disease or clinical signs of progressive disease at the data cutoff.

108 3 (18%) had stable disease, and 2 (12%) had progressive disease at the final follow-up.

109 eview committee assessed response, including progressive disease, based on imaging using modified Int

110 ion Whole-body MRI enabled identification of progressive disease before CT in most participants with

111 In the case of progressive disease, bevacizumab was combined with erlot

112 (AS) is the prototypic form of SpA in which progressive disease can lead to fusion of the spine.

113 n-mediated amyloidosis is a rare, inherited, progressive disease caused by mutations in the transthyr

114 Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary

115 Pulmonary fibrosis is a progressive disease characterized by fibroblast prolifer

116 lmonary fibrosis (IPF) is a lethal, chronic, progressive disease characterized by formation of scar t

117 Idiopathic pulmonary fibrosis (IPF) is a progressive disease characterized by interstitial remode

118 Pulmonary arterial hypertension (PAH) is a progressive disease characterized by lung endothelial ce

119 Advanced heart failure (HF) is a progressive disease characterized by recurrent hospitali

120 early postnatal development, but resulted in progressive disease characterized by reduced activity an

121 flammatory bowel diseases (IBD) are chronic, progressive diseases characterized by aberrant immune re

122 e elevated MIF and D-DT levels in males with progressive disease compared with relapsing-remitting ma

123 nts who discontinued chemotherapy because of progressive disease could cross over to the ceritinib gr

124 gressive, and 12% of patients with secondary progressive disease course (2% of eyes).

125 Progressive disease course (P=0.017), thoracic aorta inv

126 Progressive disease course (P=0.018) and carotidynia (P=

127 ith multiple sclerosis who display a rapidly progressive disease course and in whom potent pharmacoth

128 745G>A mutation generally had a less rapidly progressive disease course than the 17 cases with other

129 ever, men with MS tend to demonstrate a more progressive disease course than women, suggesting a disc

130 m HIV-1-infected patients who have the usual progressive disease course.

131 progression and conversion into a secondary progressive disease course.

132 ss, which is more prominent in patients with progressive disease course.

133 Nine patients with documented progressive disease despite all established therapy unde

134 f patients with plasma cell neoplasms die of progressive disease despite high response rates to novel

135 with median survival of 1 year or less, and progressive disease despite second-line therapy.

136 he second biopsy, abdominal imaging revealed progressive disease despite sorafenib treatment.

137 ned positive for HER1/2 and who did not have progressive disease during chemotherapy (four to eight c

138 Only two patients had progressive disease during the first two vaccine courses

139 atic or recurrent endometrial cancer who had progressive disease following one or two lines of chemot

140 or response, 48.8% stable disease, and 12.2% progressive disease for nonpancreatic GEP NET.

141 nor response, 18.2% stable disease, and 9.1% progressive disease for pancreatic NET; and 22.0% partia

142 by +/-2 SDs were identified with significant progressive disease for RV, with a decrease in RV-FAC gr

143 or response, 35.1% stable disease, and 10.8% progressive disease for the entire cohort; 54.5% partial

144 ded independent central review (BICR) showed progressive disease for the patient.

145 roven, opportunities to intervene to prevent progressive disease, founded in a thorough cellular and

146 65) for docetaxel; for stable disease versus progressive disease, hazard ratios were 0.52 (0.37-0.71)

147 : A new pattern of response, so-called hyper-progressive disease (HPD), is emerging during treatment

148 PC2 in the kidney exhibited severe, rapidly progressive disease, illustrating the importance of comp

149 as stable disease in 90% (9/10 patients) and progressive disease in 10% (1/10 patients) at 3 mo, and

150 , and stable disease in 8 of 10 patients and progressive disease in 2 of 10 patients at 6 mo.

151 Ibrutinib was discontinued due to progressive disease in 27% of patients.

152 n reasons for treatment discontinuation were progressive disease in 34 (24%) patients and adverse eve

153 al remission in 5, stable disease in 13, and progressive disease in 7 patients.

154 al remission in 14, stable disease in 2, and progressive disease in 9 patients.

155 adaptive immunity in driving persistent and progressive disease in acute MPTP-intoxicated mice.

156 Diabetic cardiomyopathy is a progressive disease in diabetic patients, and myocardial

157 actory diffuse large B-cell lymphoma (due to progressive disease in four patients, infections in thre

158 in 2 patients, a mixed response in one, and progressive disease in one.

159 which point 86 (67%) of 128 patients without progressive disease in the placebo group chose to cross

160 osis was found for those patients who showed progressive disease, in comparison with patients with cu

161 were enucleated: one at diagnosis, nine with progressive disease including three eyes treated with EB

162 oblastoma patients had no response and 7 had progressive disease, including 6 of 8 entering the study

163 h-salt diet (5-9 weeks after I/R) manifested progressive disease indicated by enhanced inflammation,

164 PGSs stratified patients with high risk for progressive disease indicated by worse prognostic outcom

165 ate that RLBP1 mutations are associated with progressive disease involving RPE atrophy and photorecep

166 Gauging the risk of developing progressive disease is a major challenge in prostate can

167 Progressive disease is characterized by hepatic leukocyt

168 , traditionally considered relapsing but non-progressive diseases, is poorly defined.

169 was an excellent inter-observer agreement in progressive disease (k=0.94, percent agreement=97.1%), s

170 Patients with progressive disease lack these immune niches, suggesting

171 IBM is a slowly progressive disease, leading to wheelchair use, on avera

172 Progressive disease leads to pathologic tissue remodelin

173 ractory patients with distant metastases and progressive disease (mean age, 71.4 y).

174 pants with disease control versus those with progressive disease (median, 121 Gy [IQR: 86-190 Gy] vs

175 vival than nonresponding patients (stable or progressive disease) (median, 19 mo vs. 7.5 mo; log-rank

176 trophy and WM abnormalities in patients with progressive disease might indicate a more independent ne

177 Importantly, these experiments establish a progressive disease model that can contribute toward ide

178 For chronic progressive diseases, mortality may not be a feasible en

179 igible for intermittent sunitinib because of progressive disease (n = 13), toxicity (n = 1), or conse

180 s were nonresponders (stable disease, n = 9; progressive disease, n = 2).

181 esponse, n = 11; stable disease, n = 17; and progressive disease, n = 8.

182 onders vs stable disease/minimal response vs progressive disease/NE, median PFS was 15.0 months (95%

183 iscontinued nivolumab for reasons other than progressive disease; nine (50%) of those had responses l

184 Biochemical progression or progressive disease occurred in 391 patients (221 [57%]

185 Idiopathic pulmonary fibrosis (IPF) is a progressive disease of the middle aged and elderly with

186 Age-related macular degeneration (AMD) is a progressive disease of the retinal pigment epithelium (R

187 or stable disease in patients with formerly progressive disease) of up to 95%, with a low incidence

188 re carcinoembryonic antigen (CEA) >80 mug/L, progressive disease on chemotherapy, size of largest les

189 ere used to screen patients with and without progressive disease on ibrutinib, and ibrutinib-naive di

190 nostic significant in patients classified as progressive disease on the basis of irRC.

191 ignificance in patients classified as having progressive disease on the basis of irRC.

192 This method identifies 41% of the later progressive diseases on CT, with no false-positives.

193 s had discontinued study drug as a result of progressive disease or clinical signs of progressive dis

194 ry endpoint was time to progression (time of progressive disease or death from any cause), with inten

195 l, defined as the time from randomisation to progressive disease or death, whichever occurred first.

196 mg orally on days 1-21 every 28 days) until progressive disease or intolerability, or single-agent i

197 cytosis (HLH) with refractory, recurrent, or progressive disease or intolerance to HLH therapy.

198 ients with advanced grades 1 and 2 NETs with progressive disease or other poor prognostic features.

199 DLBCL which, for this study, was defined as progressive disease or stable disease as best response a

200 During BEP, 15 patients died of progressive disease or toxicity, including one patient f

201 ery 4 weeks thereafter (28-day cycles) until progressive disease or toxicity.

202 ived only a single course of HDCT because of progressive disease or toxicity.

203 t-baseline scans, or discontinued because of progressive disease or treatment-related adverse events

204 Study patients were treated until progressive disease or unacceptable adverse effects occu

205 was administered (100 mg) twice a day until progressive disease or unacceptable toxic effects occurr

206 ntinuous oral ibrutinib (560 mg) daily until progressive disease or unacceptable toxic effects.

207 ory NHL received venetoclax once daily until progressive disease or unacceptable toxicity at target d

208 ed >75 years) on days 1, 8, 15, and 22 until progressive disease or unacceptable toxicity.

209 eived oral ibrutinib 420 mg once daily until progressive disease or unacceptable toxicity.

210 6 cycles with daily ibrutinib (420 mg) until progressive disease or unacceptable toxicity.

211 ed on empirical data derived from studies of progressive disease or whether treatment decisions are b

212 0.017-0.518), but increased the frequency of progressive disease (OR, 2.717; 95% CI, 1.391-5.304).

213 lth states: progression-free survival (PFS), progressive disease, or dead.

214 lasses (complete response, partial response, progressive disease, or stable disease) and in the diffe

215 ated with greater brain atrophy in secondary progressive disease over a period of short term follow-u

216 n particularly in patients who had secondary progressive disease (P (CSF) < 4 x 10(-5), P (plasma) <

217 Patients with stable disease or progressive disease (PD) after no more than 6 months of

218 lth states (progression-free survival (PFS), progressive disease (PD) and death) were analyzed in the

219 ently, we identified significant RD3 loss in progressive disease (PD) and defined its association wit

220 ging findings during treatment suggestive of progressive disease (PD) despite evidence of clinical be

221 her whole-body MRI enables identification of progressive disease (PD) earlier than CT and bone scinti

222 A limitation of this targeted therapy is progressive disease (PD) in some patients.

223 nsition, whereas those present at on-therapy progressive disease (PD) upregulated kynurenine, plasmin

224 In case of progressive disease (PD), an additional evaluation was p

225 es with stable disease (SD), 5 patients with progressive disease (PD), and 14 with HPD.

226 ations at baseline, co-acquired mutations at progressive disease (PD), and the clonal evolution remai

227 Results: Of the 4 patients with clinically progressive disease (PD), mean K(i) significantly increa

228 ntiating between pseudoprogression (PsP) and progressive disease (PD).

229 artial response [PR] v stable disease [SD] v progressive disease [PD]), disease control rate (DCR; CR

230 er irRC (n = 84), and 17.3% in patients with progressive disease per both criteria (n = 177).

231 h criteria (n = 331), 37.5% in patients with progressive disease per RECIST v1.1 but nonprogressive d

232 survived >/= 12 weeks, 84 (14%) experienced progressive disease per RECIST v1.1 but nonprogressive d

233 stages, it tends to have limited effect on a progressive disease, possibly due to adverse effects on

234 mitting and the central canal CSF surface in progressive disease, possibly implying CSF-mediated path

235 d all patients in this group died of rapidly progressive disease postrelapse.

236 ts with multiple sclerosis (MS) have primary progressive disease (PPMS).

237 Patients with MSKCC poor-risk disease or progressive disease prior to surgery had a poor outcome

238 ssible that this gray matter loss reflects a progressive disease process irrespective of medication u

239 cted lesion due to ECD for >/=3 months), and progressive disease (progression or worsening of proven

240 ier intervention with ocrelizumab in primary progressive disease, progression remains an important un

241 hree with relapsed or refractory CLL (due to progressive disease, pulmonary infection, and pneumonia;

242 isease progression (clinical or radiological progressive disease, relapse, or death from any cause).

243 st effective at discriminating patients with progressive disease requiring surgery, with an AUC of 0.

244 rsus 18% +/- 32% in patients with stable and progressive disease, respectively.

245 Glaucoma is a progressive disease responsible for the second commonest

246 Type 2 diabetes mellitus (T2DM) is a progressive disease resulting from increasing insulin re

247 Patients with progressive disease show alterations in their serum prot

248 Tumors from patients with progressive disease showed a higher variance of the intr

249 ponders (n = 6) (stable metabolic disease or progressive disease) showed a median OS of 4.4 mo (1-y a

250 asyn is likely occurring in both initial and progressive disease stages, and preventing truncation ma

251 Focusing on progressive disease stages, we could then demonstrate th

252 lysosomal storage was undetectable in iPSCs, progressive disease subtype-specific storage material wa

253 ) were significantly higher in patients with progressive disease than in patients with stable disease

254 malities was weaker in primary and secondary progressive disease than in relapsing-remitting disease.

255 Rheumatoid arthritis (RA) is a progressive disease that affects both pediatric and adul

256 Chronic wasting disease (CWD) is a fatal, progressive disease that affects cervid species, includi

257 NASH is a progressive disease that can lead to cirrhosis, cancer,

258 otrophic lateral sclerosis (ALS) is a severe progressive disease that cannot be prevented or cured.

259 ive pulmonary disease (COPD) is a common and progressive disease that is influenced by both genetic a

260 Seventeen patients (23%) had progressive disease: their PSA level rose by more than 2

261 Progressive disease thresholds for studies that did not

262 espond, and many patients eventually develop progressive disease to daratumumab monotherapy.

263 spectrum from infancy (early onset, rapidly progressive disease) to childhood/adolescence and adulth

264 to-head trials of therapies for this complex progressive disease, to answer issues such as how best t

265 has led to several small clinical trials of progressive disease treatment as adjuvant for disease-mo

266 al response (treatment success) or stable or progressive disease (treatment failure)-according to pre

267 least one high-risk feature (aged >40 years, progressive disease, tumour size >5 cm, tumour crossing

268 least one high-risk feature (aged >40 years, progressive disease, tumour size >5 cm, tumour crossing

269 ays after discontinuing treatment because of progressive disease (two [5%]) and respiratory failure (

270 ive siltuximab locally (eight) or because of progressive disease (two), adverse events (two), or othe

271 These progressive diseases typically have an insidious onset,

272 nib orally once daily (45 mg or 30 mg) until progressive disease, unacceptable toxicity, or patient w

273 e chief producers of IL-17A in patients with progressive disease undergoing liver transplantation.

274 onse + partial response, 54.3% v 49.5%), and progressive disease was 3.2% versus 5.4%, respectively.

275 Progressive disease was detected in 2 patients (7.2%) by

276 Progressive disease was detected on week 2 scans in 3 pa

277 te and partial response, stable disease, and progressive disease were defined according to the 2014 N

278 sion profiles of MSCs from IPF subjects with progressive disease were enriched for genes regulating l

279 relevant preoperative predictors of in-field progressive disease were identified.

280 th recurrent disease, partial remission, and progressive disease were retreated, with either surgery

281 increased MIF and D-DT levels in males with progressive disease were significantly correlated with t

282 Patients with stable/progressive disease were to have radiation before TME, w

283 Eight of 12 patients with recurrent/progressive disease were upstaged, 1 was downstaged, and

284 therapy protocol (8 Complete Response and 11 Progressive Disease) were evaluated for serum SEVs size,

285 There are 2 forms of this progressive disease: wet and dry.

286 Type 2 diabetes (T2D) is a progressive disease whereby there is often deterioration

287 recurrent disease after local treatment, and progressive disease while undergoing systemic treatment.

288 Cholangiopathies are a diverse group of progressive diseases whose primary cell targets are chol

289 y one third of patients experience a rapidly progressive disease with a dismal outcome.

290 Because PD is a progressive disease with a long asymptomatic phase, iden

291 Untreated severe aortic stenosis is a progressive disease with a poor prognosis.

292 Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a prevalence of 1 million perso

293 Severe alcoholic hepatitis (SAH) is often a progressive disease with high mortality and limited ster

294 ic pulmonary fibrosis (IPF) is a devastating progressive disease with limited therapeutic options.

295 CG is considered a progressive disease with variable rates of progression.

296 tocellular adenomas were more likely to show progressive disease, with hepatic nuclear factor 1alpha-

297 al centres in 12 countries who had confirmed progressive disease within 24 weeks after two or more ip

298 e imaging findings meeting RANO criteria for progressive disease within 6 months of initiating immuno

299 bevacizumab monotherapy was continued until progressive disease without significant treatment-relate

300 o change in symptoms attributed to ECD), and progressive disease (worsening of symptoms attributed to